Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Surrozen (NASDAQ:SRZN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Earnings & Valuation
This table compares Tectonic Therapeutic and Surrozen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -7.16 |
| Surrozen | $10.00 million | 3.74 | -$43.04 million | N/A | N/A |
Tectonic Therapeutic has higher earnings, but lower revenue than Surrozen.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
| Surrozen | 0 | 0 | 1 | 0 | 3.00 |
Tectonic Therapeutic currently has a consensus target price of $72.25, indicating a potential upside of 71.21%. Surrozen has a consensus target price of $45.00, indicating a potential upside of 290.63%. Given Surrozen’s higher probable upside, analysts plainly believe Surrozen is more favorable than Tectonic Therapeutic.
Risk & Volatility
Tectonic Therapeutic has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Insider & Institutional Ownership
62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 43.5% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Tectonic Therapeutic and Surrozen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
| Surrozen | N/A | -120.51% | -54.68% |
Summary
Tectonic Therapeutic beats Surrozen on 7 of the 11 factors compared between the two stocks.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
